Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. (OPTHF) is a Canadian GMP-compliant pharmaceutical drug manufacturer focused on natural psilocybin and MDMA for regulated mental health therapies. News about Optimi often centers on its role in supplying psychedelic medicines for clinical trials, prescription programs, and specialized treatment pathways in markets such as Australia, Canada, and Israel.
Investors and observers following Optimi’s news flow can expect updates on regulatory milestones, such as Health Canada inspections and Drug Establishment License developments, as well as announcements related to product launches and exports of MDMA and psilocybin capsules. Recent releases have highlighted commercial availability of psilocybin capsules for treatment-resistant depression under Australia’s Authorized Prescriber Scheme, MDMA capsules for PTSD treatment programs, and selection as a supplier for a multicenter PTSD clinical trial sponsored by Sheba Medical Center in Israel.
Corporate news also includes financing transactions, private placements of convertible debentures, and agreements with market-making and investor relations firms. Optimi additionally reports on participation in investor conferences, board changes, and strategic relationships with partners such as Mind Medicine Australia and clinical service providers involved in psychedelic-assisted psychotherapy programs.
This news page aggregates these company-issued updates, giving readers a single view of Optimi’s progress in psychedelic drug manufacturing, its involvement in regulated mental health initiatives, and its capital markets activities. For those tracking developments in pharmaceutical-grade psychedelics and their integration into formal treatment frameworks, Optimi’s news provides insight into how the company positions its MDMA and psilocybin products within evolving regulatory and clinical environments.
Optimi Health Corp. has partnered with Numinus Wellness Inc. to advance the development of a natural psilocybin capsule for a human clinical trial. A pre-clinical trial application has been submitted to Health Canada, with ongoing cultivation and validation studies at the Numinus lab in British Columbia. This initiative aims to produce standardized psilocybin dosages for various health conditions. Optimi will retain full ownership and intellectual property rights of the capsule.
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) has advanced its R&D program for a 100% Optimi-owned psychedelic capsule aimed at human clinical trials. Partnering with Numinus Wellness, Optimi is progressing towards Health Canada approvals for its psilocybin production. The firm emphasizes developing all-natural formulations, aiming for regulatory readiness and multiple revenue streams in addressing health conditions. The company has secured access to specialized laboratory services under the research agreement with Numinus, with all resulting intellectual property owned by Optimi.
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) is advancing the construction of its 20,000 sq. ft. production facility in Princeton, British Columbia. Recently, the company awarded contracts for critical interior finishing and technology installation. All required permits are secured, and advanced systems for HVAC and security are being implemented. The facility's design includes a Level 8 product vault for psilocybin, allowing secure storage with an initial capacity of 50kg, extendable to 1,250kg. City officials commend Optimi for diversifying the local economy and creating job opportunities.
Optimi Health has appointed Dr. Azim Jamal to its Advisory Board and Leah Hodges as Corporate Secretary. Dr. Jamal, a seasoned industry leader, has extensive experience in various business investments and previously served as CEO of Retirement Concepts. Leah Hodges brings over 16 years of corporate governance expertise. CEO Mike Stier emphasized the importance of governance for business success and welcomed the new appointments. Additionally, Optimi has signed an advisory agreement with fitness expert Harley Pasternak, issuing 50,000 shares initially, with up to 150,000 shares over three years, pending CSE approval.